title: Allogeneic bone marrow transplantation in patients with sensitive low-grade lymphoma or mantle cell lymphoma.
abstract: OBJECTIVE
  To report survival outcomes of allogeneic BMT in patients with low-grade lymphoma or mantle cell lymphoma (MCL).
  
  
  METHODS
  Thirty-five patients with low-grade lymphoma (48%), chronic lymphocytic leukemia (26%), or MCL (26%) underwent myeloablative allogeneic BMT from HLA-identical siblings at the Johns Hopkins Oncology Center. Patients had a median age of 46 years, a median of 2 prior treatments, and 31% were in complete remission at the time of transplantation. The preparative regimen was cyclophosphamide/total body irradiation for most patients. All grafts were T-cell depleted by counter flow centrifugal elutriation with CD34+ augmentation.
  
  
  RESULTS
  The incidence of acute GVHD grade >2 was 6% and of grades 1 to 2 was 37%. The incidence of chronic GVHD was 6%. The median follow-up time was 25 months. The rate of event-free survival (EFS) was 50% (95% confidence interval [CI], 33%-66%). Only 1 patient relapsed. The transplantation-related mortality (TRM) was 46% for all patients. The TRM was 86% for patients with resistant disease and 14% for patients with sensitive disease and <2 prior treatments; rates of EFS were 0% (95% CI, 0%-0%) and 79% (95% CI, 47%-93%), respectively.
  
  
  CONCLUSIONS
  These data show that, with T-cell depletion, the TRM and relapse rates are modest for patients with sensitive disease and <2 prior treatment courses. Thus, if there is a role for allogeneic BMT in the management of patients with these tumors, it is early in the course of the disease.
authors.affiliation: Department of Oncology, Johns Hopkins University, Baltimore, Maryland, USA.
authors.forename: J G
authors.initials: JG
authors.lastname: Berdeja
authors.forename: R J
authors.initials: RJ
authors.lastname: Jones
authors.forename: M L
authors.initials: ML
authors.lastname: Zahurak
authors.forename: S
authors.initials: S
authors.lastname: Piantadosi
authors.forename: R A
authors.initials: RA
authors.lastname: Abrams
authors.forename: M J
authors.initials: MJ
authors.lastname: Borowitz
authors.forename: G B
authors.initials: GB
authors.lastname: Vogelsang
authors.forename: S J
authors.initials: SJ
authors.lastname: Noga
authors.forename: R F
authors.initials: RF
authors.lastname: Ambinder
authors.forename: I W
authors.initials: IW
authors.lastname: Flinn
mesh_terms: D000328:Adult; D016026:Bone Marrow Transplantation / Q000379:methods / Q000401:mortality*; D005260:Female; D006086:Graft vs Host Disease; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000628:therapy; D008212:Lymphocyte Depletion; D020522:Lymphoma, Mantle-Cell / Q000401:mortality / Q000628:therapy*; D008228:Lymphoma, Non-Hodgkin / Q000401:mortality / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D015996:Survival Rate; D014184:Transplantation, Homologous; D016896:Treatment Outcome